최근 5년, 2019~현재

- 2022
Prospect of ULK1 modulators in targeting regulatory T cells. Y Park*, J Jang* Bioorg. Chem. (2022) accepted

Cell extraction method coupled with LC-QTOF MS/MS analysis for predicting neuroprotective compounds from Polygonum tinctorium. H Shin, J Jang, M K Lee, K Y Lee J Pharm Biomed Anal (2022) 220, 114988

Recent advances in the development of antidepressants targeting the purinergic P2X7 receptor. S Lee, H Ha, J Jang, Y Byun Curr Med Chem (2022) in press

Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors. T S Beyett, C To, D E Heppner, J K Rana, A M Schmoker, J Jang, D J H De Clercq, G Gomez, D A Scott, N S Gray, P A Janne, M J Eck Nat. Commun. (2022) 13, 2530

Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC. T W Gero, D E Heppner, T S Beyett, C To, S C Azevedo, J Jang, T Bunnell, F Feru, Z Li, B H Shin, K M Soroko, P C Gokhale, N S Gray, P A Janne, M J Eck, D A Scott B Bioorg. Med. Chem. Lett. (2022) 68, 128718

Allosteric Inhibition of Drug Resistant Forms of EGFR L858R mutant NSCLC. C To†, T S Beyett†, J Jang†, W W Feng, M Bahcall, H M Haikala, B H Shin, D E Heppner, J K Rana, B A Leeper, K M Soroko, M J Poitras, P C Gokhale, Y Kobayashi, K Wahid, K J Kurppa, T W Gero, M D Cameron, A Ogino, M Mushajiang, C Xu, Y Zhang, D A Scott, M J Eck, N S Gray, P A Janne Nature Cancer (2022) 3, 402-417

A novel HER2-selective kinase inhibitor is effective in HER2 mutant and amplified non-small cell lung cancer. J Son, J Jang, T S Beyett, Y Eum, H M Haikala, A Verano, M Lin, J M Hatcher, N P Kwiatkowski, P O Eser, M J Poitras, S Wang, M Xu, P C Gokhale, M D Cameron, M J Eck, N S Gray, P A Janne Cancer Res. (2022) 82, 1633-1645

- 2021
Surveillance of avian influenza viruses from 2009 to 2013 in South Korea. J-H Nam, E Espano, E-J Song, S-M Shim, W Na, S-H Jeong, J Kim, J Jang, D Song, J-K Kim Sci. Rep. (2021) 11, 23991

Neural-Cadherin Influences the Homing of Terminally Differentiated Memory CD8 T Cells to the Lymph Nodes and Bone Marrow. K H Kim, A Choi, S H Kim, H Song, S Jin, K Kim, J Jang, H Choi, Y W Jung Mol. Cells (2021) 44, 795

A Review on Pharmacological Activities and Recent Synthetic Advances of γ-Butyrolactones. J Hur, J Jang*, J Sim*. Int. J. Mol. Sci. (2021) 22, 2769

Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer - a review of patent literature. H Ha, H Kwon, T Lim, J Jang, S-K Park, Y Byun. Expert Opin. Ther. Pat. (2021) 31, 2525-2547

Structure-Activity Relationship Studies of Dipeptide-Based Hepsin Inhibitors with Arg Bioisosteres. H Kwon, H Ja, J Jeon, J Jang, S-H Son, K Lee, S-K Park, Y Byun. Bioorg. Chem. (2021) 107, 104521

- 2020
Visible-Light-Induced Cysteine-Specific Bioconjugation: Biocompatible Thiol-Ene Click Chemistry. H Choi, M Kim, J Jang*, S. Hong*. Angewandte Chemie Int. Ed. (2020) 59, 22514-22522. *co-corresponding author

Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations. J Jang†, C To† , D J H De Clercq, E Park, C M Ponthier, B H Shin, M Mushajiang, R P Nowak, E S Fischer, M J Eck, P A Janne*, N S Gray*. Angewandte Chemie Int. Ed. (2020) 59, 14481-4489. †equal contribution

- 2019
Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors. D J H De Clercq, D E Heppner, C To, J Jang, E Park, C-H Yun, M Mushajiang, B H Shin, T W Gero, D A Scott, P A Janne, M J Eck, N S Gray. ACS Med. Chem. Lett. (2019) 10, 1549-1553

Single and dual targeting of mutant EGFR with an allosteric inhibitor. C To†, J Jang†, T Chen, E Park, M Mushajiang, D J H De Clercq, M D Cameron, D E Heppner, A Yang, S E Dahlberg, K-K Wong, M J Eck, N S Gray, P A Janne. ‘ Cancer Discovery (2019) 9, 926-943. †equal contribution

Identification of small molecule inhibitors targeting the Zika virus envelope protein. J Pitts, C-Y Hsia, W Lian, J Wang, M-P Pfeil, N Kwiatkowski, Z Li, J Jang, N S Gray, P L Yang. Antiviral Res. (2019) 164, 147-153.

Small molecules targeting the flavivirus E protein with broad-spectrum activity and antiviral efficacy in Vivo. P-C Li†, J Jang†, C-Y Hsia, P Groomes, W Lian, M de Wispelaere, J D Pitts, J Wang, N Kwaitkowski, N S Gray, P L Yang. ACS Infectious Diseases (2019) 5, 460-472. †equal contribution

Discovery of fluorescent 3-heteroarylcoumarin derivatives as novel inhibitors of anaplastic lymphoma kinase. S Mah, J Jang, D Song, Y Shin, M Latif, Y Jung, S Hong. Org. Biomol. Chem. (2019) 17, 186-194.